U.S. Food and Drug Administration (USFDA) has completed the surveillance inspection at Biocon’s API facility (Site 2), located at Bengaluru, Karnataka. USFDA had conducted the said inspection between September 23-27, 2024.

Four observations were cited at the end of the Inspection, which the Company will be addressing within the stipulated time. The Company does not foresee any impact on the business.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.